Although a recent report reinforces the prominent role of TP53 mutation as a prognosis tool for CLL [55], our work lends supports to other studies which have challenged the prognostic value of aberrations in master regulators such as ATM and TP53 [56,57]. This evidence concerns the gene ATM and B-cell chronic lymphocytic leukemia.